Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association - 1 Mar 2024

Hamidi Sarah, Iyer Priyanka C, Dadu Ramona, Gule-Monroe Maria K, Maniakas Anastasios, Zafereo Mark E, Wang Jennifer R, Busaidy Naifa L, Cabanillas Maria E

Abstract excerpt

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However, patients eventually develop resistance and progress. Single-agent anti-PD-1 inhibitor spartalizumab has shown a median overall survival (mOS) of 5.9 months. Combination of immunotherapy with BRAF/MEK inhibitors (BRAF/MEKi) seems to improve outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 38226606
DOI: 10.1089/thy.2023.0573

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.PMID 38226606Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.Semantic proximity Read ↗

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity Read ↗

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.Semantic proximity Read ↗

Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Semantic proximity Read ↗

Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.Semantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.Semantic proximity Read ↗

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.